STAT+: The inside story of Enhertu’s pan-tumor approval
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
Category: biotechnology
Gas prices are hurting biotech
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions
The European Parliament has voted overwhelmingly to adopt legislation that is supposed to transform the…
STAT+: Vertex to buy Alpine Immune Sciences for $4.9 billion
Vertex Pharmaceuticals will buy Alpine Immune Sciences, a maker of protein-based medicines that harness the…
STAT+: BIO’s top lobbyist exits, signaling reorganization
WASHINGTON — The biotech industry’s largest trade group has parted ways with its top lobbyist,…
AskBio CSO steps down, has new project in stealth mode
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Cancer vaccines gain momentum, after years of disappointing results
SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade. But…
Pfizer’s plot to win the RSV vaccine race
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biotech startups post strongest financing numbers in two years
The numbers are in, and biotech startups recently closed out their best fundraising quarter in…
STAT+: Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells
The team behind Karuna Therapeutics, which was recently snapped up in a multibillion-dollar deal, on…
Sanofi resolves most Zantac litigation
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
Why is it surprising when drug executives stay true to their word? And can neoantigen…
STAT+: Weed for weight loss, and more from Biotech Land
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
How resurrecting extinct species might impact medicine
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Matt & Adam’s Take: Amylyx did the right thing by withdrawing its ALS drug. That’s rare and worthy of praise
On Thursday morning, Amylyx Pharmaceuticals announced that it would withdraw its ALS drug, Relyvrio, after…
STAT+: Amylyx to pull ALS drug from market, cut 70% of staff
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and…
STAT+: Early data from rare-disease trial put spotlight on Moderna’s efforts to turn mRNA into medicines
LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start,…
New data on liquid biopsy for colorectal cancer detection still underwhelms
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Investors funnel $275 million into Paragon Therapeutics spinout
Investors have funneled $275 million into a revamped biotech developing new psoriasis and psoriatic arthritis…
.jpg)
STAT+: As AI proliferates, biopharma companies seek to harness it in clinical trials
For around 20 years, Avi Veidman spent his days in the Israeli intelligence community, analyzing…
STAT+: Genmab to buy ProfoundBio for $1.8 billion, the latest deal focused on targeted chemotherapies
LONDON — The Danish firm Genmab said Wednesday it would acquire ProfoundBio for $1.8 billion…
STAT+: Roivant CEO: New deals could ‘materialize later this year’
Can Roivant’s business model survive its success? Roivant Sciences announced two pieces of news Tuesday:…
Lawmakers want to add more Chinese biotechs to defense list
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Gritstone Bio says personalized cancer vaccine falls short in key trial
Gritstone Bio said Monday afternoon that its personalized cancer vaccine didn’t induce more responses than…
STAT+: Roivant autoimmune drug succeeds in Phase 2 study in eye condition
A drug being developed by a Roivant subsidiary for a range of autoimmune conditions succeeded…
Verve Therapeutics ‘pauses’ tests of its gene editor for heart disease and prioritizes a backup treatment
Verve Therapeutics said Tuesday that it is pausing testing of its closely watched gene-editing treatment…
STAT+: The biotech scoreboard for the second quarter: 32 stock-moving events to watch
Here is STAT’s biotech scoreboard, our regular ledger of stock-moving biotech events, for the second…
Aardvark Therapeutics gearing up for $200 million IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Critics say U.K. decision on ALS drug could have ‘chilling effect’ on access to new genetic medicines
LONDON — Neurologists and patient advocates are up in arms over a policy decision by…
What’s Congress going to do with WuXi?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: The U.S. needs a bipartisan industrial policy for the life sciences
President Biden’s efforts to revitalize the nation’s technology-based industries, which began with semiconductors and electric…
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
Who gets to sue the FDA? Is pharma caught in a trade war? And what…
STAT+: A contrarian view on Viking Therapeutics, biotech’s hottest obesity stock
This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
How GLP-1’s moved from research labs to national TV
Today is the inaugural publishing day for Adam’s Biotech Scorecard — a subscriber-only newsletter offering…
STAT+: Why the world’s most expensive drug might not be all that overpriced
The staff of the Institute for Clinical and Economic Review, or ICER, are known as…
Who can sue the FDA? Answering Justice Alito’s question from the mifepristone arguments
WASHINGTON — Supreme Court Justice Samuel Alito had a clear question at Tuesday’s arguments over…
Brazil’s plan for low-cost CAR-Ts
New biotech newsletter launching tomorrow. Don’t miss out. Good morning, everyone. Damian here with the…
Merck’s next big thing is (probably) on the way
New biotech newsletter launching this Thursday. Don’t miss out. Hello, everyone. Damian here with a look…
STAT+: Viking Therapeutics to move its oral obesity drug into Phase 2 study after early success
Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an…
How will the Supreme Court’s mifepristone decision impact biopharma?
New biotech newsletter launching this Thursday. Don’t miss out. Hey there. Today, we discuss the…
SCOTUS’ abortion pill mifepristone case is really about the FDA
WASHINGTON — The Supreme Court on Tuesday will hear opening arguments in an abortion medication…
STAT+: Patient advocates clash over wisdom of ‘approving drugs faster and faster’
NEW YORK — Over 30 years ago, Gregg Gonsalves and other AIDS activists persuaded Congress…
STAT+: During the pandemic, were great vaccines bad business? A company-by-company review
It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people…
.jpg)
FDA approves new drug to protect immune compromised from Covid-19
The Food and Drug Administration on Friday authorized a new antibody to protect immunocompromised individuals…
STAT+: How biotech investors spot opportunity when stocks are down — and up
Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors…
EU adviser says Illumina merger was not problematic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Drug development was once a marathon. New tools and timelines are turning it into a sprint
Drug development is more of a sprint than a marathon these days, thanks to more…
Listen: Live! From the STAT Breakthrough Summit East
Is there a cure for allergies? Has the FDA become too flexible? And which drugs…
STAT+: Regeneron’s plot to ‘cure’ allergies
George Yancopoulos is in touch with his teenage self. After 35 years as head scientist…
STAT+: Feng Zhang suggests Editas didn’t move quickly enough to find product targets
When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas…